ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "interleukins (IL)"

  • Abstract Number: 1805 • 2012 ACR/ARHP Annual Meeting

    The Pro-Fibrotic Cytokines IL-33 and IL-13 Modulates Dermal Fibrosis Via the A2A Adenosine Receptor

    Ross C. Radusky1, Jessica L. Feig2, Bruce N. Cronstein3, Andrew G. Franks Jr.4 and Edwin SL Chan1, 1Medicine, New York University School of Medicine, New York, NY, 2Medicine. Department of Translational Medicine, New York University School of Medicine, New York, NY, 3Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, 4Dermatology & Medicine (Rheumatology), New York University, New York, NY

    Background/Purpose: We have previously demonstrated that the nucleoside adenosine mediates collagen production and induce dermal fibrosis in in vitro and in vivo models. IL–13 expression…
  • Abstract Number: 877 • 2012 ACR/ARHP Annual Meeting

    Aberrant Expression of BAFF Receptor (BR3) in Peripheral Monocytes of Patients with Primary Sjögren’s Syndrome Impacts Abnormal Activation of BAFF Signaling Through IKK-Alphaand IKK-Beta

    Keiko Yoshimoto1, Maiko Tanaka2, Masako Kojima2, Hideko Ogata2, Hideto Kameda1, Katsuya Suzuki1, Tohru Abe3 and Tsutomu Takeuchi4, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Dept Int Med Saitama Med Ctr, Saitama Medical School, Kawagoe-shi Saitama, Japan, 4Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: B cell activating factor belonging to the TNF superfamily (BAFF) regulates proliferation, differentiation and survival of B cells and plays a pivotal role in…
  • Abstract Number: 2031 • 2012 ACR/ARHP Annual Meeting

    Safety and Efficacy of Anakinra in Patients with Deficiency of Interleukin-1 Receptor Antagonist

    Gina A. Montealegre1, Adriana Almeida de Jesus2, Dawn C. Chapelle3, Paul Dancey4, Joost Frenkel5, Annet van Royen-Kerkhoff6, Ronit Herzog7, Giovanna Ciocca8, Rafael F. Rivas-Chacon8, Ann M. Reed9, Nicole Plass3, Ivona Aksentijevich10, Polly J. Ferguson11, Suvimol C. Hill12, Edward Cowen13 and Raphaela T. Goldbach-Mansky3, 1NIAMS, Bethesda, MD, 2Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 3Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 4Health Science Centre, Memorial University of Newfoundland, St Johns, Canada, 5Wilhelmina Childrens Hospital, University of Utrecht, Utrecht, Netherlands, 6University of Utrecht, Utrecht, Netherlands, 7Cornell University, New York, NY, 8Miami Children's Hospital, Miami, FL, 9Rheumatology, Mayo Clinic, Rochester, MN, 10Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 11Dept of Pediatrics--Rheum, University of Iowa Carver College of Medicine, Iowa City, IA, 12Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD, 13Dermatology Consultation Servce, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Background/Purpose: Deficiency of interleukin-1 receptor antagonist (DIRA) is a neonatal-onset autoinflammatory syndrome caused by mutations in IL1RN gene and clinically characterized by a perinatal onset…
  • Abstract Number: 901 • 2012 ACR/ARHP Annual Meeting

    Colony-Stimulating Factor (CSF) Receptor 1 Blockade Overcomes Overlapping Effects of M-CSF and Interleukin-34 On Myeloid Differentiation and Gene Expression to Reduce Inflammation in Human and Murine Models of Rheumatoid Arthritis

    Samuel Garcia1, Linda M. Hartkamp2, Inge E. van Es2, Haishan Lin3, Li Long3, Emma L. Masteller3, Brian R. Wong3, Paul P. Tak4 and Kris A. Reedquist2, 1Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 3Five Prime Therapeutics, Inc., South San Francisco, CA, 4Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands

    Background/Purpose: Disease activity and response to therapy in RA correlates with changes in synovial macrophage numbers and their products. M-CSF or IL-34 stimulation of their…
  • Abstract Number: 2021 • 2012 ACR/ARHP Annual Meeting

    The Schedule of Administration of Canakinumab in Cryopyrin Associated Periodic Syndrome Is Driven by the Phenotype Severity Rather Than the Age

    Roberta Caorsi1, Loredana Lepore2, Francesco Zulian3, Maria Alessio4, Achille Stabile5, Antonella Insalaco6, Martina Finetti1, Antonella Battagliese4, Giorgia Martini7, Chiara Bibalo8, Alberto Martini9 and Marco Gattorno1, 1Second Division of Paediatrics, G. Gaslini Institute, Genova, Italy, 2Istituto Burlo Garofolo, Trieste, Italy, 3Department of Pediatrics, University of Padua, Padova, Italy, 4Department of Pediatrics,, Federico II Hospital, Napoli, Italy, 5DipartimentoPediatria, Policlinico Gemelli, Roma, Italy, 6Department of Pediatric Rheumatology, Ospedale Pediatrico Bambino Gesù, Roma, Italy, 7Department of Pediatrics,, University of Padua, Padua, Italy, 8Pediatrics-Univ of Trieste, Ospedale-Infantile Trieste, Trieste, Italy, 9Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH

    Background/Purpose: to identify the optimal regimen for the treatment with Canakinumab in CAPS patients and, in patients receiving both Anakinra and Canakinumab during their disease…
  • Abstract Number: 899 • 2012 ACR/ARHP Annual Meeting

    A Role for Soluble Interleukin-6 Receptor As an Antagonist of Interleukin-27 Signaling

    Misato Hashizume1, Keiko Esaki2 and Yoshihiro Matsumoto1, 1Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2Discovery Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan

    Background/Purpose: Recently, it has been reported that interleukin (IL)-27 treatment reduces inflammation and ameliorates arthritis in collagen-induced arthritis mice. IL-27 is a heterodimeric cytokine composed…
  • Abstract Number: 2079 • 2012 ACR/ARHP Annual Meeting

    Anti-Interleukin-6 Receptor Antibody Improves Systemic Osteoporosis in a Mice Model of Glucose-6-Phosphate Isomerase-Induced Arthritis

    Hiroto Yoshida1, Miho Suzuki1, Misato Hashizume1, Keisuke Tanaka2, Masashi Shiina2, Isao Matsumoto3, Takayuki Sumida3 and Yoshihiro Matsumoto2, 1Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan, 3Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan

    Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of osteoporosis and osteoporotic fracture. In addition to the primary risk factors for osteoporosis, osteoporosis…
  • Abstract Number: 894 • 2012 ACR/ARHP Annual Meeting

    Genetic Variants in the IL-4 and IL-4 Receptor Genes in Association with the Severity of Joint Damage in Rheumatoid Arthritis: A Study in Seven Cohorts

    A. Krabben1, A. G. Wilson2, R. Knevel1, A. Zhernakova3, E. Brouwer3, E. Lindqvist4, T. Saxne4, G. Stoeken-Rijsbergen1, J. A. B. van Nies1, D. P. C. de Rooy1, T.W.J. Huizinga1, B. P. C. Koeleman5, R. E. M. Toes1, P. K. Gregersen6 and A. H. M. van der Helm-van Mil1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, 3Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands, 4Rheumatology, Lund University, Lund, Sweden, 5Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, 6Genomics and Human Genetics, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY

    Background/Purpose: The severity of RA is reflected by the severity of radiological joint destruction. It is highly variable between patients and up to 58% of…
  • Abstract Number: 2077 • 2012 ACR/ARHP Annual Meeting

    IL-6 Blockade Augments the Anti-Inflammatory Effect without Increasing the Side Effects of Steroids in Collagen-Induced Arthritis

    Miho Suzuki1, Hiroto Yoshida2, Misato Hashizume1, Masashi Shiina2, Keisuke Tanaka1 and Yoshihiro Matsumoto1, 1Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan

    Background/Purpose: Steroids are the main therapy for chronic inflammatory diseases. They are very effective, but induce many side effects, such as osteoporosis, making it important…
  • Abstract Number: 1062 • 2012 ACR/ARHP Annual Meeting

    Identification of Highly Potent and Selective Interleukin-1 Receptor-Associated Kinase 4 Inhibitors for the Treatment of Rheumatic Diseases

    Divya Chaudhary1, Shaughnessy Robinson2, Craig E. Masse1, Matthew D. Wessel2, Shawn Watts2, Jeremy Greenwood2, Mee Shelley2, Mark Brewer2, Geraldine Harriman1, Leah L. Frye2, Ronald T. Wester1, Rosana Kapeller1 and Donna Romero1, 125 First Street Suite 404, Nimbus Discovery, Inc., Cambridge, MA, 2Schrödinger, Inc., New York, NY

    Background/Purpose:   Interleukin-1 receptor-associated kinase 4 (IRAK4) is a key mediator of the innate immune response orchestrated by interleukin-1 receptor (IL-1R), interleukin-18 receptor (IL-18R), IL-33…
  • Abstract Number: 2084 • 2012 ACR/ARHP Annual Meeting

    ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats

    Shunji Yamazaki1, Masamichi Inami1, Misato Ito1, Yasutomo Fujii1, Kaori Hanaoka1, Kaoru Yamagami1, Kenji Okuma1, Yoshiaki Morita1, Shohei Shirakami2, Takayuki Inoue2, Susumu Miyata3 and Yasuyuki Higashi1, 1Pharmacology Research Labs, Astellas Pharma Inc., Tsukuba, Japan, 2Chemistry Research Labs, Astellas Pharma Inc., Tsukuba, Japan, 3Research Planning & Administration, Astellas Pharma Inc., Tsukuba, Japan

    Background/Purpose: The Janus kinase (JAK) family of enzymes plays a key role in cytokine signaling, which is involved in the pathogenic events of immune-mediated disorders…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences